An unexpectedly large decline in demand for vaccines against, among other things, covid-19 and RS-virus creates more headwind than expected for the company.
The revenue this year is now expected to remain at 1.5-2.5 billion dollars. Previously, it was at 2.5-3.5 billion, with an average forecast among analysts of 2.9 billion according to Bloomberg.
According to preliminary calculations, Moderna's sales in 2024 amounted to 3.0-3.1 billion dollars.
